A PhaseⅡ/Ⅲ, Randomized, Double-blind, Placebo-controlled Trial to Evaluate QL1706 Perioperative Treatment in Combination With Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Iparomlimab/tuvonralimab (Primary) ; Cisplatin; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer; Thoracic neoplasms
- Focus Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 04 Mar 2025 New trial record